GlassScriptPhysician profile
Oliver C Galita
NPI 1346206489
$1,865.52
in general payments reported to CMS, 2019-2025
21 companies · $438 in 2025
The $438 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $74.70 · 2021: $36.05 · 2022: $142 · 2023: $411 · 2024: $399 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $353.45 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $286.24 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $243.65 | 2019-2025 | |
| Pfizer INC. | $181.23 | 2019-2025 | |
| Alk-Abello, INC | $115.72 | 2024-2025 | Neffy, Grastek, Odactra |
| Kaleo, INC. | $115.31 | 2022-2024 | Auvi-Q |
| Cranial Technologies, INC | $111.49 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $63.59 | 2025 | Jornay Pm |
| Tris Pharma INC | $58.31 | 2019-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $55.54 | 2025 | Qelbree |
| Adlon Therapeutics L.P. | $39.45 | 2019 | |
| Neos Therapeutics, LP | $37.86 | 2019-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $35.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.32 | 2023-2024 | Flumist Quadrivalent |
| Phadia US INC. | $29.26 | 2020-2023 | Immunocap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $24.29 | 2025 | Neffy |
| Aytu Biopharma, INC. | $18.99 | 2024 | Karbinal |
| Vyne Pharmaceuticals INC. | $18.28 | 2020 | |
| Seqirus USA INC | $17.77 | 2025 | Flucelvax |
| Sobi, INC | $15.80 | 2023 | |
| Vertical Pharmaceuticals, LLC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Galita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.